

**Report From Agency**

**STATE OF WISCONSIN  
CONTROLLED SUBSTANCES BOARD**

---

**IN THE MATTER OF RULE-MAKING : REPORT TO THE LEGISLATURE  
PROCEEDINGS BEFORE THE : ON CLEARINGHOUSE RULE 06-058  
CONTROLLED SUBSTANCES BOARD : (s. 227.19 (3), Stats.)**

---

**I. THE PROPOSED RULE:**

The proposed rule, including the analysis and text, is attached.

**II. REFERENCE TO APPLICABLE FORMS:**

No new or revised forms are required by these rules.

**III. FISCAL ESTIMATES:**

The department finds that the proposed rule will have no significant fiscal impact. The department finds that this rule has no significant fiscal effect on the private sector.

**IV. STATEMENT EXPLAINING NEED:**

By final rule of the Drug Enforcement Administration (DEA), adopted effective March 10, 2004, 2,5 dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) and N-benzylpiperazine (BZP) were classified as schedule I controlled substances under the federal Controlled Substances Act (CSA). Neither 2C-T-7 or BZP have been so scheduled under the Wisconsin Controlled Substances Act in Chapter 961, Stats. This rule-making will bring the treatment of these drugs into conformity with that at the federal level.

**V. NOTICE OF PUBLIC HEARING:**

A public hearing was held on September 7, 2006. There were no appearances at the public hearing nor were any written comments received.

**VI. RESPONSE TO LEGISLATIVE COUNCIL STAFF RECOMMENDATIONS:**

There were no recommendations suggested in the Clearinghouse Report.

**VII. FINAL REGULATORY FLEXIBILITY ANALYSIS:**

These rules will have no significant economic impact on small businesses, as defined in s. 227.114 (1), Stats.

CSB 2.31, 2.32 CR06-058 (2C-T-7 & BZP) Report to Leg 11-16-06